DataRoom AM: Leighton's China boost

The construction giant's planned sale of John Holland gets a booster shot from the China free-trade agreement, while mum and dad investors flock to the Medibank stock offering.

The Chinese free-trade deal is drawing mixed reviews from the gamut of impacted parties, but one company that may have cause for celebration is Leighton Holdings as it looks to accelerate its asset sales plan.

Elsewhere, Medibank Private races toward a very successful ASX debut, Alinta Energy faces a valuation quandary, Anchorage eyes off a Pacific Brands division and Estia Health receives some good news ahead of its IPO.


{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device

Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device

Register as a new member

(using a different email)

Related Articles